ZA200606679B - Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation - Google Patents

Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation

Info

Publication number
ZA200606679B
ZA200606679B ZA200606679A ZA200606679A ZA200606679B ZA 200606679 B ZA200606679 B ZA 200606679B ZA 200606679 A ZA200606679 A ZA 200606679A ZA 200606679 A ZA200606679 A ZA 200606679A ZA 200606679 B ZA200606679 B ZA 200606679B
Authority
ZA
South Africa
Prior art keywords
modulators
inflammation
treatment
furosemide
derivatives
Prior art date
Application number
ZA200606679A
Other languages
English (en)
Inventor
Minnich Anne
Eishingdrelo Haifeng
Lang Han-Jochen
Kuntzweiler Theresa
Angelastro Michael
Original Assignee
Aventis Pharma Inc
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc, Sanofi Aventis Deutschland filed Critical Aventis Pharma Inc
Publication of ZA200606679B publication Critical patent/ZA200606679B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200606679A 2004-02-20 2006-08-11 Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation ZA200606679B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
ZA200606679B true ZA200606679B (en) 2008-01-30

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606679A ZA200606679B (en) 2004-02-20 2006-08-11 Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation

Country Status (24)

Country Link
US (2) US7232811B2 (xx)
EP (1) EP1718292A1 (xx)
JP (1) JP2007523166A (xx)
KR (1) KR20060127141A (xx)
CN (1) CN1921845A (xx)
AR (1) AR047747A1 (xx)
AU (1) AU2005216879B2 (xx)
BR (1) BRPI0506792A (xx)
CA (1) CA2557444A1 (xx)
CR (1) CR8528A (xx)
EC (1) ECSP066777A (xx)
IL (1) IL177086A (xx)
MA (1) MA28373A1 (xx)
ME (1) MEP21108A (xx)
MX (1) MXPA06008612A (xx)
NO (1) NO20064237L (xx)
NZ (1) NZ548830A (xx)
RS (1) RS20060473A (xx)
RU (1) RU2006133540A (xx)
SG (1) SG164305A1 (xx)
TN (1) TNSN06234A1 (xx)
TW (1) TW200538109A (xx)
WO (1) WO2005082350A1 (xx)
ZA (1) ZA200606679B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
EP1968603A4 (en) * 2006-01-03 2013-01-16 Algebra Inc THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
MX2008009354A (es) * 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
WO2008052190A2 (en) 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
US7556931B2 (en) 2009-07-07
NZ548830A (en) 2010-03-26
EP1718292A1 (en) 2006-11-08
IL177086A0 (en) 2006-12-10
CR8528A (es) 2007-06-08
AR047747A1 (es) 2006-02-15
AU2005216879A1 (en) 2005-09-09
CA2557444A1 (en) 2005-09-09
IL177086A (en) 2010-06-16
BRPI0506792A (pt) 2007-05-22
RS20060473A (xx) 2008-08-07
TW200538109A (en) 2005-12-01
AU2005216879B2 (en) 2009-12-10
WO2005082350A8 (en) 2005-12-08
NO20064237L (no) 2006-09-19
JP2007523166A (ja) 2007-08-16
RU2006133540A (ru) 2008-03-27
ECSP066777A (es) 2006-11-16
WO2005082350A1 (en) 2005-09-09
CN1921845A (zh) 2007-02-28
MA28373A1 (fr) 2006-12-01
US7232811B2 (en) 2007-06-19
MEP21108A (en) 2010-06-10
TNSN06234A1 (en) 2007-12-03
SG164305A1 (en) 2010-09-29
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
US20070213391A1 (en) 2007-09-13
MXPA06008612A (es) 2007-01-25

Similar Documents

Publication Publication Date Title
ZA200606679B (en) Furosemide derivatives as modulators of HM74 and their use for the treatment of inflammation
ZA200710966B (en) 2-Amino-4-Phenylquinazoline derivatives and their use as HSP90 modulators
PL1868600T3 (pl) Spirocykliczne pochodne cykloheksanu do leczenia uzależnienia od substancji
IL232313A (en) Modulators of indoleamine 2,3-dioxigenase and methods of use of the above
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
HK1097271A1 (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
IL172621A0 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ZA200705540B (en) Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
IL182136A0 (en) Novel pyrimidine derivatives and their use as ppar-alpha modulators
EP1720563A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
IL159892A0 (en) Use of quinonoid derivatives of cannabinoids in the treatment of malignancies
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
PL1879585T3 (pl) Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
PL378212A1 (pl) Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy
PL378197A1 (pl) Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
AU2004906798A0 (en) Pharmaceutical composition for the treatment of skin conditions
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
IL182987A0 (en) Treatment of inflammation